HRP20161234T1 - Cjepiva koja sadrže toplinski osjetljive transgene - Google Patents
Cjepiva koja sadrže toplinski osjetljive transgene Download PDFInfo
- Publication number
- HRP20161234T1 HRP20161234T1 HRP20161234TT HRP20161234T HRP20161234T1 HR P20161234 T1 HRP20161234 T1 HR P20161234T1 HR P20161234T T HRP20161234T T HR P20161234TT HR P20161234 T HRP20161234 T HR P20161234T HR P20161234 T1 HRP20161234 T1 HR P20161234T1
- Authority
- HR
- Croatia
- Prior art keywords
- bacterium
- temperature
- mesophilic
- sensitive
- essential
- Prior art date
Links
- 108700019146 Transgenes Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241000894006 Bacteria Species 0.000 claims 44
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 108091033319 polynucleotide Proteins 0.000 claims 13
- 102000040430 polynucleotide Human genes 0.000 claims 13
- 239000002157 polynucleotide Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 6
- 230000001580 bacterial effect Effects 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 241000557614 Colwellia sp. Species 0.000 claims 2
- 241000589599 Francisella tularensis subsp. novicida Species 0.000 claims 2
- 241000187488 Mycobacterium sp. Species 0.000 claims 2
- 241000607149 Salmonella sp. Species 0.000 claims 2
- 241000490596 Shewanella sp. Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 241000589567 Brucella abortus Species 0.000 claims 1
- 241001136175 Burkholderia pseudomallei Species 0.000 claims 1
- 241001508395 Burkholderia sp. Species 0.000 claims 1
- 241000589994 Campylobacter sp. Species 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 241000488157 Escherichia sp. Species 0.000 claims 1
- 241000589601 Francisella Species 0.000 claims 1
- 206010017329 Francisella infections Diseases 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000606841 Haemophilus sp. Species 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 241000186366 Mycobacterium bovis Species 0.000 claims 1
- 241001440871 Neisseria sp. Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000519582 Pseudoalteromonas sp. Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 206010039438 Salmonella Infections Diseases 0.000 claims 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 1
- 241000607764 Shigella dysenteriae Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 241000194022 Streptococcus sp. Species 0.000 claims 1
- 241000607284 Vibrio sp. Species 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940065181 bacillus anthracis Drugs 0.000 claims 1
- 229940056450 brucella abortus Drugs 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 206010039447 salmonellosis Diseases 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 229940007046 shigella dysenteriae Drugs 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1014—Hydroxymethyl-, formyl-transferases (2.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Claims (17)
1. Na temperaturu osjetljiva (engl. temperature-sensitive, TS) bakterija, gdje je na temperaturu osjetljiva bakterija mezofilna bakterija koja obuhvaća jednu ili više kodirajućih sekvenci esencijalnih nukleinskih kiselina koje kodiraju polipeptid iz psihrofilne bakterije, gdje su te kodirajuće sekvence nukleinskih kiselina umetnute u genom te mezofilne bakterije putem homologne rekombinacije čime je funkcionalno zamijenjen u mezofilnoj bakteriji homolog TS esencijalnog polinukleotida i gdje je na temperaturu osjetljiva mezofilna bakterija za uporabu u dobivanju imunog odgovora na temperaturno osjetljivu mezofilnu bakteriju u subjektu.
2. Na temperaturu osjetljiva bakterija za uporabu prema zahtjevu 1, gdje su kodirajuće sekvence nukleinskih kiselina operativno vezano za promotor.
3. Na temperaturu osjetljiva bakterija za uporabu prema zahtjevu 1, gdje jedna ili više kodirajućih sekvenci esencijalnih nukleinskih kiselina kodiraju NAD ovisnu ligazu i imaju barem 80% identičnosti sekvence prema nukleotidnoj sekvenci prikazanoj u sekvenci s identifikacijskim brojem (SEQ ID NO): 1, 3, 5, 7 ili 17.
4. Na temperaturu osjetljiva bakterija za uporabu prema bilo kojem od zahtjeva 1 do 3, dalje obuhvaća terapijski učinkovitu količinu adjuvansa.
5. Na temperaturu osjetljiva bakterija za uporabu prema bilo kojem od zahtjeva 1-4, gdje je imuni odgovor protektivni imuni odgovor.
6. Na temperaturu osjetljiva bakterija za uporabu prema bilo kojem od zahtjeva 1-5, gdje subjekt ima bakterijsku infekciju, latentnu bakterijsku infekciju ili postoji rizik od dobivanja bakterijske infekcije.
7. Na temperaturu osjetljiva bakterija za uporabu prema zahtjevu 6, gdje je bakterijska infekcija M. tuberculosis, Salmonella ili Francisella infekcija.
8. Postupak izrade rekombinantne na temperaturu osjetljive bakterije, a koji obuhvaća:
1. uvođenje nukleinske kiseline u genom mezofilne bakterije koja kodira jednu ili više kodirajućih sekvenci esencijalnih nukleinskih kiselina koje pak kodiraju polipeptid iz psihrofilne bakterije, čime je funkcionalno zamijenjen u mezofilnoj bakteriji homolog jedne ili više kodirajućih sekvenci esencijalnih nukleinskih kiselina, gdje je protein kojeg kodira sekvenca esencijalne nukleinske kiseline operativan na temperaturi nižoj od 30°C i neoperativan na temperaturi većoj od oko 30°C, poželjno gdje je psihrofilna bakterija operativna na temperaturi od oko -10°C do oko 30°C ili neoperativna na temperaturi većoj od oko 30°C, poželjno gdje je psihrofilna bakterija Colwellia sp., Psuedoalteromonas sp., ili Shewanella sp., ili je mezofilna bakterija operativna na temperaturi odabranoj iz raspona od oko 10°C do oko 50°C, poželjno je mezofilna bakterija fermentativni mikrobni soj ili soj za bioremedijaciju.
9. Postupak prema zahtjevu 8, gdje protein kojeg kodira sekvenca esencijalne nukleinske kiseline obuhvaća aminokiselinsku sekvencu s barem 80% identičnosti sekvence prema aminokiselinskoj sekvenci prikazanoj u SEQ ID NO: 2, 4, 6, 8 ili 18.
10. Postupak prema zahtjevu 8 ili 9, koji dalje obuhvaća:
uzgoj kulture rekombinantnih TS bakterija na temperaturi gdje je protein kodiran polinukleotidom operativan, pri čemu te rekombinantne TS bakterije proizvode niz peptida;
povećanje temperature uzgoja do temperature na kojoj protein kodiran molekulom TS nukleinske kiseline nije operativan;
održavanje takvog uzgoja kroz određeno vrijeme dovoljno da se ubiju rekombinantne TS bakterije; i
prikupljanje ubijenih rekombinantnih TS bakterija.
11. Postupak pripreme rekombinantnih TS bakterija koje sadrže esencijalni peptid, a koji obuhvaća:
probir psihrofilnog mikrobnog genoma radi otkrivanja esencijalnog polinukleotida u njemu koji daje temperaturnu osjetljivost bakteriji po ekspresiji konstruiranja konstrukta nukleinske kiseline koji sadrži esencijalni polinukleotid i jednu ili više kontrolnih sekvenci operativno vezanih za polinukleotid;
umetanje konstrukta nukleinske kiseline u genom odabrane domaćinske stanice mezofilne bakterije čime je funkcionalno zamijenjen u odabranoj domaćinskoj stanici mezofilne bakterije homolog esencijalnog polinukleotida, gdje esencijalni polinukleotid kodira protein operativan na temperaturi nižoj od oko 30°C i neoperativan na temperaturi većoj od oko 30°C;
uzgoj kulture domaćinske stanice mezofilne bakterije koja ima esencijalni polinukleotid na temperaturi nižoj od oko 30°C da se potvrdi vijabilnost domaćinske stanice mezofilne bakterije koja ima esencijalni polinukleotid;
daljnji uzgoj kulture domaćinske stanice mezofilne bakterije koja ima esencijalni polinukleotid na temperaturi većoj od oko 30°C da se utvrdi je li ubijena domaćinska stanica mezofilne bakterije koja ima esencijalni polinukleotid; i
ako je domaćinska stanica mezofilne bakterije koja ima esencijalni polinukleotid ubijena, slijedi umetanje konstrukta nukleinske kiseline u genom odabrane odredišne domaćinske stanice mezofilne bakterije, čime je funkcionalno zamijenjen u odabranoj odredišnoj domaćinskoj stanici mezofilne bakterije homolog esencijalnog polinukleotida, čime nastaje rekombinanta TS bakterija.
12. Postupak prema zahtjevu 11, gdje je mezofilna bakterijska stanica domaćin stanica Francisella novicida i gdje je mezofilna bakterijska odredišna stanica Salmonella sp. ili Mycobacterium sp.
13. Pripravak koji sadrži na temperaturu osjetljivu bakterijsku stanicu domaćina napravljenu postupkom prema zahtjevima 8 - 12.
14. Na temperaturu osjetljiva bakterija za uporabu prema zahtjevu 1, gdje je ta mezofilna bakterija M. tuberculosis, Bacillus anthracis, Brucella abortus, Burkholderia pseudomallei, Haemophilus influenzae, Mycobacterium bovis, Salmonella typhi, Shigella dysenteriae, Staphylococcus aureus, Streptococcus pneumoniae, Yersinia pestis ili Francisella novicida.
15. Na temperaturu osjetljiva bakterija za uporabu prema zahtjevu 1, gdje je ta mezofilna bakterija Mycobacterium sp., Haemophilus sp., Vibrio sp., Escherichia sp., Salmonella sp., Streptococcus sp., Burkholderia sp., Campylobacter sp., Neisseria sp., i Francisella sp.
16. Na temperaturu osjetljiva bakterija za uporabu prema zahtjevu 1, gdje je psihrofilna bakterija Colwellia sp., Pseudoalteromonas sp., ili Shewanella sp.
17. Na temperaturu osjetljiva bakterija za uporabu prema zahtjevu 1, gdje su kodirajuće sekvence nukleinskih kiselina spojene za postranu (engl. flanking) DNA te mezofilne bakterije.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24938509P | 2009-10-07 | 2009-10-07 | |
| US32263410P | 2010-04-09 | 2010-04-09 | |
| EP10821511.2A EP2486133B1 (en) | 2009-10-07 | 2010-10-07 | Vaccines comprising heat-sensitive transgenes |
| PCT/CA2010/001561 WO2011041886A1 (en) | 2009-10-07 | 2010-10-07 | Vaccines comprising heat-sensitive transgenes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161234T1 true HRP20161234T1 (hr) | 2016-12-02 |
Family
ID=43856334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161234TT HRP20161234T1 (hr) | 2009-10-07 | 2016-09-27 | Cjepiva koja sadrže toplinski osjetljive transgene |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8778683B2 (hr) |
| EP (1) | EP2486133B1 (hr) |
| CN (1) | CN102782138A (hr) |
| AU (1) | AU2010305273B2 (hr) |
| BR (1) | BR112012009401A2 (hr) |
| CA (1) | CA2776922A1 (hr) |
| ES (1) | ES2594485T3 (hr) |
| HR (1) | HRP20161234T1 (hr) |
| HU (1) | HUE029386T2 (hr) |
| WO (1) | WO2011041886A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020517722A (ja) * | 2017-04-28 | 2020-06-18 | カンザス ステイト ユニバーシティ リサーチ ファウンデーション | 標的遺伝子破壊方法及び免疫原性組成物 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5376369A (en) * | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
| US5270202A (en) | 1989-11-03 | 1993-12-14 | Syamal Raychaudhuri | Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen |
| US5585103A (en) | 1991-07-25 | 1996-12-17 | Idec Pharmaceutical Corporation | Induction of cytotoxic T-lymphocyte responses |
| US5709860A (en) | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
| US5662907A (en) | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
| ATE356630T1 (de) | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
| WO2001046428A1 (fr) * | 1999-12-21 | 2001-06-28 | Japan Science And Technology Corporation | Souches de vaccin contre des infections a bacteries pathogenes |
| ATE400644T1 (de) | 2003-10-13 | 2008-07-15 | Helmholtz Infektionsforschung | Transgene organismen mit niedrigerer wachstumstemperatur |
| US8168421B2 (en) * | 2005-12-09 | 2012-05-01 | University Of Georgia Research Foundation, Inc. | Microbial vaccine and vaccine vector |
| GB2444903A (en) * | 2006-12-21 | 2008-06-25 | Secr Defence | Live Francisella vaccine, inactivated at gene FTT1564 |
-
2010
- 2010-10-07 CN CN2010800555715A patent/CN102782138A/zh active Pending
- 2010-10-07 US US13/496,723 patent/US8778683B2/en not_active Expired - Fee Related
- 2010-10-07 ES ES10821511.2T patent/ES2594485T3/es active Active
- 2010-10-07 HU HUE10821511A patent/HUE029386T2/en unknown
- 2010-10-07 BR BR112012009401A patent/BR112012009401A2/pt not_active IP Right Cessation
- 2010-10-07 AU AU2010305273A patent/AU2010305273B2/en not_active Ceased
- 2010-10-07 EP EP10821511.2A patent/EP2486133B1/en not_active Not-in-force
- 2010-10-07 CA CA2776922A patent/CA2776922A1/en not_active Abandoned
- 2010-10-07 WO PCT/CA2010/001561 patent/WO2011041886A1/en active Application Filing
-
2013
- 2013-03-12 US US13/795,445 patent/US9580478B2/en active Active
-
2016
- 2016-09-27 HR HRP20161234TT patent/HRP20161234T1/hr unknown
-
2017
- 2017-01-24 US US15/414,111 patent/US20170136111A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010305273B2 (en) | 2016-09-29 |
| EP2486133B1 (en) | 2016-06-29 |
| EP2486133A1 (en) | 2012-08-15 |
| US8778683B2 (en) | 2014-07-15 |
| WO2011041886A8 (en) | 2011-06-09 |
| EP2486133A4 (en) | 2013-10-16 |
| US9580478B2 (en) | 2017-02-28 |
| AU2010305273A1 (en) | 2012-04-19 |
| US20120189661A1 (en) | 2012-07-26 |
| US20170136111A1 (en) | 2017-05-18 |
| US20130177589A1 (en) | 2013-07-11 |
| ES2594485T3 (es) | 2016-12-20 |
| BR112012009401A2 (pt) | 2017-02-21 |
| WO2011041886A1 (en) | 2011-04-14 |
| CN102782138A (zh) | 2012-11-14 |
| HUE029386T2 (en) | 2017-02-28 |
| CA2776922A1 (en) | 2011-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003234043B2 (en) | Immunogenic sequences | |
| ES2601577T3 (es) | Proteínas insecticidas | |
| DK2287300T3 (en) | Bacterial toxin vaccine | |
| DK2341149T3 (en) | Use of CRISPR-associated genes (Cas) | |
| HRP20161397T1 (hr) | Plazmid bez antibiotika | |
| HRP20171624T1 (hr) | Biotehnološka proizvodnja hondroitina | |
| HRP20161234T1 (hr) | Cjepiva koja sadrže toplinski osjetljive transgene | |
| CN110564704B (zh) | 百合花青素苷转运LhGST基因的克隆及其应用 | |
| CN106967744B (zh) | 一种利用自杀载体消除沙门菌中多拷贝质粒的方法 | |
| TW202309291A (zh) | 用於室內空氣修復之組合物及方法 | |
| JP6249456B2 (ja) | 藍藻においてプラスチック原料を生産する方法 | |
| DK2576604T3 (en) | DIFFOCINES AND METHODS OF USING THEREOF | |
| Jiang et al. | Whole-genome sequence of Bacillus cereus AR156, a potential biocontrol agent with high soilborne disease biocontrol efficacy and plant growth promotion | |
| WO2007129087A1 (en) | Plasmid curing | |
| US20240011024A1 (en) | Crispr spacer tags for labeling and/or identifying bacteria, and methods of using the same | |
| Hsiao et al. | Transcription of Xanthomonas campestris prt1 gene encoding protease 1 increases during stationary phase and requires global transcription factor Clp | |
| WO2018106578A1 (en) | Oral e. coli vector-based vaccine for prevention of coccidiosis in poultry | |
| Zhou et al. | The utility of affinity-tags for detection of a streptococcal protein from a variety of streptococcal species | |
| Mercier et al. | Horizontal gene transfer by natural transformation in soil environment | |
| Zegeye et al. | Efficient electrotransformation of bacillus thuringiensis for gene manipulation and expression | |
| AU2008200749A1 (en) | Promoters for regulation of plant gene expression | |
| Hayakawa et al. | Temperature-dependent self-splicing group I introns in the flagellin genes of the thermophilic Bacillus species | |
| Kim et al. | Investigation of possible horizontal gene transfer from transgenic rice to soil microorganisms in paddy rice field | |
| CN105294845A (zh) | 大麦抗叶锈病蛋白及其编码基因与应用 | |
| WO2024107843A1 (en) | Stabilized achromosomal dynamic active systems and uses thereof |